米非司酮联合曲普瑞林治疗子宫肌瘤的临床疗效及安全性研究  

The study of the clinical efficacy and safety of mifepristone combined with triptorelin in the treatment of uterine fibroids

作　　者：李敬香[1] 蒋素英[1] 陈惠云[1] 吴钦兰[1] 王宏波[1] 燕军[1] 

机构地区：[1]广州医科大学附属深圳沙井医院妇产科,广东深圳518104

出　　处：《中国医药科学》2015年第8期37-39,共3页China Medicine And Pharmacy

基　　金：广东省深圳市宝安区科技局资助项目(20110522)

摘　　要：目的探讨米非司酮联合曲普瑞林联合治疗子宫肌瘤的临床疗效及安全性。方法将182例子宫肌瘤患者按照抽签随机取样法将其分为对照组(n=91)和观察组(n=91)。对照组给予复方米非司酮片口服;观察组在此基础上给予注射用醋酸曲普瑞林肌肉注射。观察比较两组患者治疗前后子宫体积、肌瘤体积,促卵泡激素、雌二醇及血红蛋白水平变化。比较两组患者总有效率、不良反应发生率及复发率。结果治疗前,两组患者各临床指标比较差异均无统计学意义(P>0.05)。治疗后两组患者各临床指标均明显改善;观察组血红蛋白水平显著高于对照组(P<0.05),其余指标均显著低于对照组(P<0.05)。观察组有效率显著高于对照组(P<0.05),复发率显著低于对照组(P<0.05),不良反应发生率比较差异无统计学意义(P>0.05)。结论米非司酮联合曲普瑞林能够有效改善子宫肌瘤患者的各临床指标,有效率显著高于单纯用药,并且安全性高,值得在临床上推广应用。Objective To explore the clinical efficacy and safety of mifepristone combined with triptorelin in the treatment of uterine fibroids. Methods 182 cases of patients with uterine fibroids were selected and were randomly divided into the control group （n=91） and observation group （n=91）. The patients in the control group were given oral compound mifepristone tablets while patients in the observation group were given muscle triptorelin acetate for injection based on the treatment on group A. The changes of the size of the uterus, the volume of uterine fibroids, Follicle-stimulating hormone, estradiol and the level of hemoglobin in the patients of the two groups were observed and compared before and after the treatment. The total effective rate, incidence of adverse reactions and recurrence rate of patients in two groups were compared. Results Before treatment, the differences of the clinical indexes of patients in two groups were not statistically significant （P〉0.05）. After treatment, the clinical indexes of the patients in two groups were improved significantly. The level of hemoglobin the observation group was significantly higher than the control group （P〈0.05） and the other indexes were significantly lower than those in control group （P 〈0.05）. The effective rate in the observation group was significantly higher than that of the control group （P〈0.05） but the recurrence rate was significantly lower than that of the control group （P 〈 0.05）. The incidence of adverse reaction was not statistically significant （P〉0.05）. Conclusion the treatment of mifepristone combined with triptorelin can effectively improve the clinical indexes of patients with uterine fibroids and efficiency is significantly higher than that of the pure medicine. This method of treatment is much safer and is worth the clinical application.

关 键 词：子宫肌瘤 米非司酮 曲普瑞林 有效性 安全性 

分 类 号：R737.33[医药卫生—肿瘤]